FDA cleared the BD Veritor System for SARS-CoV-2 from BD Diagnostic Solutions / Becton, Dickinson & Company on Oct 27, 2026 under K261379, a dual track 510(k). The device falls under product code QVF, Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings, regulated at 21 CFR 866.3982 as a Class 2 device. The review panel was Microbiology.
FDA logged the submission as received on Apr 27, 2026. The decision came 183 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.
This is the only decision on file for BD Diagnostic Solutions / Becton, Dickinson & Company in the last 12 months of the tracker.